Board of Directors
Mr. Groninger is CEO of LBS Technologies, Inc., a private biotechnology company focusing on RNA amplification and cellular therapy, and the lead investor in Expression Pathology, Inc.’s Series A Preferred offering. Mr. Groninger founded and is President of The Bay South Company, a Richmond, Virginia-based provider of financial advisory and investment banking services. From 1988 through 1994, he served as a Managing Director, Investment Banking Division, of PaineWebber Inc., now UBS. Mr. Groninger is a member of the board of directors of NPS Pharmaceuticals, Inc. and Cygne Designs, Inc., both publicly held companies, and LBS Technologies. Mr. Groninger received an M.B.A. degree from Harvard Business School and a B.S. from Yale University. He is a CPA and a CFA.
Casey P. Eitner
Prior to helping start up Expression Pathology in 2002, Mr. Eitner was with Life Technologies (Invitrogen) from 1986 to 2001, where he served as VP Business Development & New Ventures, responsible for creating several successful business initiatives and partnerships, and as Executive VP of the Molecular Diagnostics Division, divested as Digene (now Qiagen), which pioneered DNA-based diagnostic tests for papilloma virus and cervical cancer. Previously Mr. Eitner started the US subsidiary of Labsystems Oy, Helsinki, Finland, and served in several strategic management and marketing roles with Mallinckrodt, Inc., St. Louis and Montreal, commercializing innovative diagnostic products and technologies.